- Home
- AYTU vs BCLI Comparison
AYTU vs BCLI Comparison
Compare AYTU & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- BCLI
- Stock Information
- Founded
- AYTU N/A
- BCLI 2000
- Country
- AYTU United States
- BCLI United States
- Employees
- AYTU N/A
- BCLI N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AYTU Health Care
- BCLI Health Care
- Exchange
- AYTU Nasdaq
- BCLI Nasdaq
- Market Cap
- AYTU 9.8M
- BCLI 9.1M
- IPO Year
- AYTU N/A
- BCLI N/A
- Fundamental
- Price
- AYTU $1.38
- BCLI $2.28
- Analyst Decision
- AYTU
- BCLI Strong Buy
- Analyst Count
- AYTU 0
- BCLI 1
- Target Price
- AYTU N/A
- BCLI $30.00
- AVG Volume (30 Days)
- AYTU 37.2K
- BCLI 127.2K
- Earning Date
- AYTU 02-12-2025
- BCLI 11-14-2024
- Dividend Yield
- AYTU N/A
- BCLI N/A
- EPS Growth
- AYTU N/A
- BCLI N/A
- EPS
- AYTU N/A
- BCLI N/A
- Revenue
- AYTU $79,759,000.00
- BCLI N/A
- Revenue This Year
- AYTU N/A
- BCLI N/A
- Revenue Next Year
- AYTU N/A
- BCLI N/A
- P/E Ratio
- AYTU N/A
- BCLI N/A
- Revenue Growth
- AYTU N/A
- BCLI N/A
- 52 Week Low
- AYTU $1.30
- BCLI $1.05
- 52 Week High
- AYTU $3.45
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- AYTU 33.90
- BCLI 67.08
- Support Level
- AYTU $1.30
- BCLI $1.45
- Resistance Level
- AYTU $1.47
- BCLI $2.40
- Average True Range (ATR)
- AYTU 0.12
- BCLI 0.22
- MACD
- AYTU -0.01
- BCLI 0.10
- Stochastic Oscillator
- AYTU 17.78
- BCLI 83.50
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.